TrainPain

Company Overview

Snapshot

Founded in July 2017 by Elan Schneider and Laurence Nash, TrainPain operates with 1–10 employees. The company has secured $1M in total capital across one funding round from two investors. In September 2018, TrainPain received funding from Merchavia Holdings and eHealth Ventures.

Business overview

TrainPain develops a science-based digital product designed to improve mental and emotional well-being for individuals experiencing neuropathic and fibromyalgia pain. The company's core technology targets sensory-perceptual processes to reduce pain-related hypersensitivity through neuroplasticity exercises. This platform integrates wearable hardware with personalized sensory training games and a virtual pain coach, available in both virtual reality and smartphone formats. TrainPain operates within the Health Tech & Life Sciences sector, specifically focusing on Digital Healthcare and Digital Therapeutics, serving patients and providers in the United States and globally.

Strategic signal

In December 2020, TrainPain reported successful trial results for its fibromyalgia treatment, indicating significant progress in validating its game-based neuro-rehabilitation technology. This success suggests a positive trajectory for the company's digital therapeutics platform, potentially attracting further investment and adoption within the chronic pain management market.

Company Intelligence Q&A

What is TrainPain's primary focus?

TrainPain focuses on developing neuroplasticity training technology to improve mental and emotional well-being for individuals with neuropathic and fibromyalgia pain, utilizing digital therapeutics.

When was TrainPain founded?

TrainPain was founded in July 2017.

Who are the founders of TrainPain?

TrainPain was founded by Elan Schneider and Laurence Nash.

What was a significant early milestone for TrainPain?

In November 2018, TrainPain was accepted into the eHealth Ventures incubator, a program focused on funding and growing early-stage Israeli digital health companies.

What was a key development regarding TrainPain's clinical validation?

In December 2020, TrainPain reported successful trial results for its treatment targeting fibromyalgia.